TTPH, Tetraphase Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TTPH, Tetraphase Pharmaceuticals

TTPH 2.200

-3.5%

Jul 28 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: scaram(o)uche	1/28/2016 3:45:58 PM
	Read Replies (1) of 80

The product that recently flopped, an excerpt from the latest quarterly PR..... In September 2015, the Company announced that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI) did not meet the primary endpoint of statistical non-inferiority compared to levofloxacin. The Company plans to provide an update after it has discussed the data and a path forward with the regulatory agencies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next